A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
NCT00394901
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Visual Analogue Scale (VAS) of pain is higher than 40 mm.
- Pain is sustained for more than 3 months after healing of herpes zoster skin rash.
- Malignancy within the past 2 years.
- Patients who have undergone neurolytic or neurosurgical therapy for postherpetic
neuralgia.
- Creatinine clearance = 30 mL/min (estimated from serum creatinine, body weight, age,
and sex using the Cockcroft and Gault equation, by omitting any decimal fractions).
- Patients having other severe pain which may impair the self assessment of the pain due
to postherpetic neuralgia.
- Skin conditions in the affected dermatome that could alter sensation.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Anniston, Alabama
- Litchfield Park, Arizona
- Phoenix, Arizona
- Atlantis, Florida
- Clearwater, Florida
- Largo, Florida
- Miami, Florida
- Palm Beach Gardens, Florida
- Sunrise, Florida
- Tampa, Florida
- Topeka, Kansas
- Towson, Maryland
- N. Dartmouth, Massachusetts
- Ann Arbor, Michigan
- Edina, Minnesota
- St Louis, Missouri
- Asheville, North Carolina
- Cleveland, Ohio
- Dayton, Ohio
- Kettering, Ohio
- Altoona, Pennsylvania
- Duncansville, Pennsylvania
- Bryan, Texas
- Dallas, Texas
- Houston, Texas
- San Antonio, Texas
- Richmond, Virginia
- Vina del Mar, V Region
- Moscow,
- St. Petersburg,
- St. Petersburg,
- Yaroslavl,
- Cadiz,
- Madrid,
- Ourense,
- Sevilla,
- Valencia,
- Linkoping,
- Stockholm,
- Stockholm,
- Dnipropetrovsk,
- Donetsk,
- Kharkiv,
- Kharkiv,
- Kharkiv,
- Kyiv,
- Odessa,
- Simferopol,
- Bexhill on Sea, East Sussex
- Blackpool, Lancashire
- Weybridge, Surrey
- Solihull,
- Nagoya, Aichi
- Ichikawa, Chiba
- Urayasu, Chiba
- Kasuga, Fukuoka
- Kasuya-gun, Fukuoka
- Maebaru, Fukuoka
- Maebashi, Gunma
- Takasaki, Gunma
- Asahikawa, Hokkaido
- Sapporo, Hokkaido
- Akashi, Hyogo
- Amagasaki, Hyogo
- Himeji, Hyogo
- Kobe, Hyogo
- Nishinomiya, Hyogo
- Tsuchiura, Ibaraki
- Sagamihara, Kanagawa
- Yokohama, Kanagawa
- Sendai, Miyagi
- Beppu, Ohita
- Kishiwada, Osaka
- Takatsuki, Osaka
- Kawaguchi, Saitama
- Kitamoto, Saitama
- Tokorozawa, Saitama
- Adachi-ku, Tokyo
- Arakawa-ku, Tokyo
- Bunkyo-ku, Tokyo
- Edogawa-ku, Tokyo
- Mitaka, Tokyo
- Nakano-ku, Tokyo
- Shinagawa-ku, Tokyo
- Shinjuku-ku, Tokyo
- Suginami-ku, Tokyo
- Toshima-ku, Tokyo
- Fukuoka,
- Fukushima,
- Osaka,
- Saitama,
- Leesburg, Florida
- Lexington, Kentucky
- Raleigh, North Carolina
- Jekintown, Pennsylvania
- Senftenberg, A-3541
- Wien,
- Schwerin,
- Pretoria, Gauteng
- Paarl, Western Cape
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia | |||
Official Title ICMJE | A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin In The Treatment Of Postherpetic Neuralgia | |||
Brief Summary | The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Care Provider) Primary Purpose: Treatment | |||
Condition ICMJE | Neuralgia, Postherpetic | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 372 | |||
Original Enrollment ICMJE | 360 | |||
Actual Study Completion Date ICMJE | November 2007 | |||
Actual Primary Completion Date | November 2007 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Japan | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00394901 | |||
Other Study ID Numbers ICMJE | A0081120 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer, Inc. | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | February 2010 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |